C12N 7/08
Inactivation or attenuation by serial passage of virus
Official title: {Inactivation or attenuation} by serial passage of virus
C12N7/08 (Inactivation or attenuation by serial passage of virus) appears on 14 US grants and 19 published applications in this corpus.
Search patents in C12N- Granted patents
- 14
- Published applications
- 19
- Assignees
- 11
- Inventors
- 49
- Latest grant
- 23 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 1 | 0 |
| 2011 | 1 | 1 |
| 2012 | 1 | 0 |
| 2013 | 0 | 1 |
| 2014 | 1 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 2 |
| 2017 | 2 | 0 |
| 2018 | 0 | 4 |
| 2019 | 2 | 1 |
| 2020 | 1 | 0 |
| 2021 | 0 | 2 |
| 2022 | 2 | 1 |
| 2023 | 0 | 1 |
| 2024 | 1 | 1 |
| 2025 | 1 | 1 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Canine parvovirus23 Jun 2026US 12,661,395 B2Intervet Inc.
- System and method to determine critical process parameters for a continuous viral inactivation reactor to design and manufacture same28 Jan 2025US 12,209,257 B2Boehringer Ingelheim International GmbH
- Cells for producing influenza virus and method for producing influenza virus23 Apr 2024US 11,964,009 B2Japan Science and Technology Agency
- Live-attenuated yellow fever virus strain adapted to grow on Vero cells and vaccine composition comprising the same18 Oct 2022US 11,471,521 B2Sanofi Pasteur Limited
- Live-attenuated yellow fever virus strain adapted to grow on Vero cells and vaccine composition comprising the same27 Sep 2022US 11,452,772 B2Sanofi Pasteur Limited
- Canine parvovirus10 Sep 2026US 2026/0263590 A1Intervet Inc.
- System and method to determine critical process parameters for a continuous viral inactivation reactor to design and manufacture same10 Apr 2025US 2025/0115882 A1Boehringer Ingelheim International GmbH
- Attenuated alphavirus28 Nov 2024US 2024/0390476 A1Zoetis Services LLC
- Canine Parvovirus21 Dec 2023US 2023/0405110 A1Intervet Inc.
- Live-Attenuated Yellow Fever Virus Strain Adapted to Grow on Vero Cells and Vaccine Composition Comprising the Same17 Feb 2022US 2022/0047692 A1Sanofi Pasteur Limited
Most cited
By later US patents
- Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions8US 7,695,939 B2Bavarian Nordic A/S · 2010
- Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions4US 7,964,397 B2Bavarian Nordic A/S · 2011
- Immortalised chicken embryo fibroblasts1US 10,428,316 B2Intervet Inc. · 2019
- Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions1US 8,329,466 B2Bavarian Nordic A/S · 2012